NASDAQ:EVOK - Evoke Pharma Stock Price, News, & Analysis

$0.59
-0.03 (-4.84 %)
(As of 06/24/2019 04:00 PM ET)
Today's Range
$0.59
Now: $0.59
$0.6201
50-Day Range
$0.5680
MA: $0.63
$0.72
52-Week Range
$0.53
Now: $0.59
$3.40
Volume90,255 shs
Average Volume556,836 shs
Market Capitalization$13.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.23 per share

Profitability

Net Income$-7,570,000.00

Miscellaneous

Employees6
Market Cap$13.72 million
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) posted its quarterly earnings results on Wednesday, May, 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.04. View Evoke Pharma's Earnings History.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Evoke Pharma.

What price target have analysts set for EVOK?

2 brokerages have issued 1-year target prices for Evoke Pharma's shares. Their predictions range from $1.33 to $5.00. On average, they anticipate Evoke Pharma's share price to reach $3.1650 in the next twelve months. This suggests a possible upside of 436.4% from the stock's current price. View Analyst Price Targets for Evoke Pharma.

What is the consensus analysts' recommendation for Evoke Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evoke Pharma.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. HC Wainwright analysts commented, "We remind investors that Evoke had previously received a Complete Response Letter (CRL) from the FDA on the New Drug Application (NDA) for Gimoti. Since the FDA did not request any additional clinical trials and, furthermore, cited no safety issues with the drug, there may still be some hope for Gimoti to be resubmitted to the agency and eventually approved. Evoke plans to start manufacturing registration batches of Gimoti this quarter through its partner, not rated), a global contract development and manufacturing organization. This should place Evoke in a position to provide FDA with additional acceptance criteria support for the proposed droplet size distribution and other pump performance characteristics of the nasal sprayer." (5/28/2019)
  • 2. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (5/7/2019)

Has Evoke Pharma been receiving favorable news coverage?

Press coverage about EVOK stock has trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evoke Pharma earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Evoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 897,500 shares, a decrease of 23.1% from the April 30th total of 1,166,700 shares. Based on an average daily trading volume, of 843,800 shares, the short-interest ratio is currently 1.1 days. Approximately 6.3% of the shares of the stock are sold short. View Evoke Pharma's Current Options Chain.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (0.40%) and Virtu Financial LLC (0.45%). View Institutional Ownership Trends for Evoke Pharma.

Which major investors are buying Evoke Pharma stock?

EVOK stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP and Virtu Financial LLC. View Insider Buying and Selling for Evoke Pharma.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $0.59.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $13.72 million. The specialty pharmaceutical company earns $-7,570,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe.View Additional Information About Evoke Pharma.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is http://www.evokepharma.com/.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  520
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel